5-nitro-1H-indazole-3-carboxylic acid (4-methylsulphamoylmethylphenyl)-amide | 660412-02-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-nitro-1H-indazole-3-carboxylic acid (4-methylsulphamoylmethylphenyl)-amide
• 英文别名: 5-Nitro-1H-indazole-3-carboxylic acid (4-methylsulfamoylmethyl-phenyl)-amide；N-[4-(methylsulfamoylmethyl)phenyl]-5-nitro-1H-indazole-3-carboxamide
• CAS: 660412-02-2
• 化学式: C₁₆H₁₅N₅O₅S
• 分子量: 389.392
• InChiKey: HGNCHXJDBBMVAP-UHFFFAOYSA-N

物化性质

• 密度：
  1.567±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  158
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5-nitro-1H-indazole-3-carboxylic acid (4-methylsulphamoylmethylphenyl)-amide 、 在 palladium on activated charcoal 氢气 作用下， 以 DMF (N,N-dimethyl-formamide) 、 乙醇 为溶剂， 反应 3.0h， 生成 5-amino-1H-indazole-3-carboxylic acid (4-methylsulphamoylmethylphenyl)amide 、
  参考文献：
  名称：

  [EN] 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS
  [FR] COMPOSES 1H-INDAZOLE-3-CARBOXAMIDE UTILISES EN TANT QU'INHIBITEURS DE KINASES CYCLINE-DEPENDANTES (CDK)

  摘要：

  本发明提供了一种式(I)化合物，用于预防或治疗由细胞周期蛋白依赖性激酶介导的疾病状态或条件：其中A是R2基团或CH2-R2，其中R2是具有3至12个环成员的碳环或杂环基团；B是键或具有最多3个原子（选自C、N、S和O）的链长的不饱和链连接基团；R1是氢或选自SO2Rb、SO2NR7R8、CONR7R8、NR7R9以及具有3至7个环成员的碳环和杂环基团；R3至R9在说明书中定义，但不包括化合物N-[(吗啉-4-基)苯基-1H-吲唑-3-甲酰胺]和N-[4-(乙酰氨基磺酰基)苯基-1H-吲唑-3-甲酰胺]。

  公开号：

  WO2004014864A1
• 作为产物：
  描述：

  5-硝基吲唑-3-羧酸 、 4-氨基苯基-N-甲基甲烷磺酰胺 在 水 、 二氯甲烷 、 title compound 作用下， 反应 0.06h， 生成 5-nitro-1H-indazole-3-carboxylic acid (4-methylsulphamoylmethylphenyl)-amide
  参考文献：
  名称：

  1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors

  摘要：

  该发明提供了化合物(I)的使用，用于预防或治疗由细胞周期依赖性激酶介导的疾病状态或病情：其中A是R2基团或CH2-R2基团，其中R2是具有3到12个环成员的碳环或杂环基团；B是键或具有链长高达3个C、N、S和O中选择的原子的非环状连接基团；R1是氢或从SO2Rb、SO2NR7R8、CONR7R8、NR7R9和具有3到7个环成员的碳环或杂环基团中选择的基团；R3、R4、R5和R6相同或不同，且每个都从氢、卤素、羟基、三氟甲基、氰基、硝基、羧基、氨基、具有3到12个环成员的碳环或杂环基团中选择；Ra-Rb基团其中Ra是键、O、CO、X1C(X2)、C(X2)X1、X1C(X2)X1、S、SO、SO2、NRc、SO2NRc或NRcSO2；Rb从具有3到12个环成员的碳环或杂环基团和C1-8烃基组中选择，可选地被一个或多个从羟基、氧代、卤素、氰基、硝基、氨基、单个或双个C1-4烃基氨基、具有3到12个环成员的碳环或杂环基团中选择的取代基所取代，其中C1-8烃基组的一个或多个碳原子可选择被O、S、SO、SO2、NRc、X1C(X2)、C(X2)X1或X1C(X2)X1所取代；Rc是氢或C1-4烃基；X1是O、S或NRc，X2是═O、═S或═NRc；R7从氢和可选地被一个或多个从羟基、氧代、卤素、氰基、硝基、氨基、单个或双个C1-4烃基氨基、具有3到12个环成员的碳环或杂环基团中选择的取代基所取代的C1-8烃基中选择，其中C1-8烃基的一个或多个碳原子可选择被O、S、SO、SO2、NRc、X1C(X2)、C(X2)X1或X1C(X2)X1所取代；R8从R7和具有3到12个环成员的碳环或杂环基团中选择；R9从R8、COR8和SO2R8中选择；或NR7R8或NR7R9各自可以形成具有5到12个环成员的杂环基团；但不包括化合物N-[(morpholin-4-yl)phenyl-1H-indazole-3-carboxamide和N-[4-(acetylaminosulphonyl)phenyl-1H-indazole-3-carboxamide]。

  公开号：

  US20060135589A1

文献信息

• 3-(Carbonyl) 1h-indazole compounds as cyclin dependent kinases (cdk) inhibitors
  申请人：Berdini Valerio

  公开号：US20060135516A1

  公开（公告）日：2006-06-22

  The invention provides a compound of the formula (I): wherein E is O, S, or NH; G is selected from hydrogen; carbocyclic and heterocyclic groups having from 3 to 12 ring members; and acyclic C 1-8 hydrocarbyl groups optionally substituted; provided that E—G is not OH or SH and further provided that E—G does not contain the group O—O; two adjacent moieties selected from R 3 , R 4 , R 5 and R 6 , together with the carbon atoms to which they are attached, form a fused heterocyclic group having from 5 to 7 ring members and 1, 2 or 3 ring heteroatoms selected from N, O and S; and the other two moieties selected from R 3 , R 4 , R 5 and R 6 are the same or different and are each as defined in the description. The Invention also provides compounds of the formula (I) for use as inhibitors of cyclin dependent kinases and for use in the treatment of disease states and conditions mediated by cyclin dependent kinases.

  本发明提供了式（I）的化合物：其中E为O，S或NH；G选择自氢；具有3至12个环成员的碳环和杂环基团；以及可选地被取代的C1-8烷基基团；前提是E-G不是OH或SH，并且进一步提供E-G不包含O-O基团；从R3、R4、R5和R6中选择的两个相邻基团，与它们附着的碳原子一起形成具有5至7个环成员和1、2或3个N、O和S杂原子的融合杂环基团；而从R3、R4、R5和R6中选择的另外两个基团相同或不同，并且每个基团如描述中所定义。本发明还提供了式（I）的化合物，用作细胞周期依赖性激酶的抑制剂，并用于治疗由细胞周期依赖性激酶介导的疾病状态和病情。
• [EN] 1H-INDAZOLE-3-CARBOXAMIDE COMPOUNDS AS CYCLIN DEPENDENT KINASES (CDK) INHIBITORS<br/>[FR] COMPOSES 1H-INDAZOLE-3-CARBOXAMIDE UTILISES EN TANT QU'INHIBITEURS DE KINASES CYCLINE-DEPENDANTES (CDK)
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2004014864A1

  公开（公告）日：2004-02-19

  The invention provides a compound of the formula (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase: wherein A is a group R2 or CH2-R2 where R2 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; B is a bond or an acyclic linker group having a linking chain length of up to 3 atoms selected from C, N, S and O; R1 is hydrogen or a group selected from SO2Rb,SO2NR7R8,CONR7R8,NR7R9 and carbocyclic and heterocyclic groups having from 3 to 7 ring members; R3, to R9 are defined in the description but excluding the compounds N-[(morpholin-4-yl)phenyl-1H-indazole-3-carboxamide and N-[4-(acetylaminosulphonyl)phenyl-1H-indazole-3-carboxamide.

  本发明提供了一种式(I)化合物，用于预防或治疗由细胞周期蛋白依赖性激酶介导的疾病状态或条件：其中A是R2基团或CH2-R2，其中R2是具有3至12个环成员的碳环或杂环基团；B是键或具有最多3个原子（选自C、N、S和O）的链长的不饱和链连接基团；R1是氢或选自SO2Rb、SO2NR7R8、CONR7R8、NR7R9以及具有3至7个环成员的碳环和杂环基团；R3至R9在说明书中定义，但不包括化合物N-[(吗啉-4-基)苯基-1H-吲唑-3-甲酰胺]和N-[4-(乙酰氨基磺酰基)苯基-1H-吲唑-3-甲酰胺]。
• 1h-Indazole-3-carboxamide compounds as cyclin dependent kinase (cdk) inhibitors
  申请人：Berdino Valerio

  公开号：US20060135589A1

  公开（公告）日：2006-06-22

  The invention provides a compound of the formula (I) for use in the prophylaxis or treatment of a disease state or condition mediated by a cyclin dependent kinase: wherein A is a group R 2 or CH 2 —R 2 where R 2 is a carbocyclic or heterocyclic group having from 3 to 12 ring members; B is a bond or an acyclic linker group having a linking chain length of up to 3 atoms selected from C, N, S and O; R 1 is hydrogen or a group selected from SO 2 R b , SO 2 NR 7 R 8 , CONR 7 R 8 , NR 7 R 9 and carbocyclic and heterocyclic groups having from 3 to 7 ring members; R 3 , R 4 , R 5 and R 6 are the same or different and are each selected from hydrogen, halogen, hydroxy, trifluoromethyl, cyano, nitro, carboxy, amino, carbocyclic and heterocyclic groups having from 3 to 12 ring members; a group R a —R b wherein R a is a bond, O, CO, X 1 C(X 2 ), C(X 2 )X 1 , X 1 C(X 2 )X 1 , S, SO, SO 2 , NR c , SO 2 NR c or NR c SO 2 ; and R b is selected from hydrogen, carbocyclic and heterocyclic groups having from 3 to 12 ring members, and a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C 1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C 1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO 2 , NR c , X 1 C(X 2 ), C(X 2 )X 1 or X 1 C(X 2 )X 1 ; R c is hydrogen or C 1-4 hydrocarbyl; X 1 is O, S or NR c and X 2 is ═O, ═S or ═NR c ; R 7 is selected from hydrogen and a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from hydroxy, oxo, halogen, cyano, nitro, amino, mono- or di-C 1-4 hydrocarbylamino, carbocyclic and heterocyclic groups having from 3 to 12 ring members and wherein one or more carbon atoms of the C 1-8 hydrocarbyl group may optionally be replaced by O, S, SO, SO 2 , NR c , X 1 C(X 2 ), C(X 2 )X 1 or X 1 C(X 2 )X 1 ; R 8 is selected from R 7 and carbocyclic and heterocyclic groups having from 3 to 12 ring members; R 9 is selected from R 8 , COR 8 and SO 2 R 8 ; or NR 7 R 8 or NR 7 R 9 may each form a heterocyclic group having from 5 to 12 ring members; but excluding the compounds N-[(morpholin-4-yl)phenyl-1H-indazole-3-carboxamide and N-[4-(acetylaminosulphonyl)phenyl-1H-indazole-3-carboxamide.

  该发明提供了化合物(I)的使用，用于预防或治疗由细胞周期依赖性激酶介导的疾病状态或病情：其中A是R2基团或CH2-R2基团，其中R2是具有3到12个环成员的碳环或杂环基团；B是键或具有链长高达3个C、N、S和O中选择的原子的非环状连接基团；R1是氢或从SO2Rb、SO2NR7R8、CONR7R8、NR7R9和具有3到7个环成员的碳环或杂环基团中选择的基团；R3、R4、R5和R6相同或不同，且每个都从氢、卤素、羟基、三氟甲基、氰基、硝基、羧基、氨基、具有3到12个环成员的碳环或杂环基团中选择；Ra-Rb基团其中Ra是键、O、CO、X1C(X2)、C(X2)X1、X1C(X2)X1、S、SO、SO2、NRc、SO2NRc或NRcSO2；Rb从具有3到12个环成员的碳环或杂环基团和C1-8烃基组中选择，可选地被一个或多个从羟基、氧代、卤素、氰基、硝基、氨基、单个或双个C1-4烃基氨基、具有3到12个环成员的碳环或杂环基团中选择的取代基所取代，其中C1-8烃基组的一个或多个碳原子可选择被O、S、SO、SO2、NRc、X1C(X2)、C(X2)X1或X1C(X2)X1所取代；Rc是氢或C1-4烃基；X1是O、S或NRc，X2是═O、═S或═NRc；R7从氢和可选地被一个或多个从羟基、氧代、卤素、氰基、硝基、氨基、单个或双个C1-4烃基氨基、具有3到12个环成员的碳环或杂环基团中选择的取代基所取代的C1-8烃基中选择，其中C1-8烃基的一个或多个碳原子可选择被O、S、SO、SO2、NRc、X1C(X2)、C(X2)X1或X1C(X2)X1所取代；R8从R7和具有3到12个环成员的碳环或杂环基团中选择；R9从R8、COR8和SO2R8中选择；或NR7R8或NR7R9各自可以形成具有5到12个环成员的杂环基团；但不包括化合物N-[(morpholin-4-yl)phenyl-1H-indazole-3-carboxamide和N-[4-(acetylaminosulphonyl)phenyl-1H-indazole-3-carboxamide]。